» Articles » PMID: 36345837

A Data-informed Approach Using Individualised Dispensing Patterns to Estimate Medicine Exposure Periods and Dose from Pharmaceutical Claims Data

Overview
Publisher Wiley
Date 2022 Nov 8
PMID 36345837
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmaceutical claims data are often used as the primary information source to define medicine exposure periods in pharmacoepidemiological studies. However, often critical information on directions for use and the intended duration of medicine supply are not available. In the absence of this information, alternative approaches are needed to support the assignment of exposure periods. This study summarises the key methods commonly used to estimate medicine exposure periods and dose from pharmaceutical claims data; and describes a method using individualised dispensing patterns to define time-dependent estimates of medicine exposure and dose. This method extends on important features of existing methods and also accounts for recent changes in an individual's medicine use. Specifically, this method constructs medicine exposure periods and estimates the dose used by considering characteristics from an individual's prior dispensings, accounting for the time between prior dispensings and the amount supplied at prior dispensings. Guidance on the practical applications of this method is also provided. Although developed primarily for application to databases, which do not contain duration of supply or dose information, use of this method may also facilitate investigations when such information is available and there is a need to consider individualised and/or changing dosing regimens. By shifting the reliance on prescribed duration and dose to determine exposure and dose estimates, individualised dispensing information is used to estimate patterns of exposure and dose for an individual. Reflecting real-world individualised use of medicines with complex and variable dosing regimens, this method offers a pragmatic approach that can be applied to all medicine classes.

Citing Articles

Prevalence of central nervous system-active polypharmacy in a cohort of older adults in Argentina.

Ferraris A, Angriman F, Barrera T, Penizzotto P, Faerman S, Rivadeneira W BJPsych Open. 2024; 10(6):e190.

PMID: 39468835 PMC: 11698161. DOI: 10.1192/bjo.2024.798.


A data-informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data.

Bharat C, Degenhardt L, Pearson S, Buizen L, Wilson A, Dobbins T Pharmacoepidemiol Drug Saf. 2022; 32(3):352-365.

PMID: 36345837 PMC: 10947320. DOI: 10.1002/pds.5567.

References
1.
Hempenius M, Luijken K, de Boer A, Klungel O, Groenwold R, Gardarsdottir H . Quality of reporting of drug exposure in pharmacoepidemiological studies. Pharmacoepidemiol Drug Saf. 2020; 29(9):1141-1150. PMC: 7539966. DOI: 10.1002/pds.5020. View

2.
Nielsen S, Degenhardt L, Hoban B, Gisev N . A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2015; 25(6):733-7. DOI: 10.1002/pds.3945. View

3.
Bharat C, Degenhardt L, Pearson S, Buizen L, Wilson A, Dobbins T . A data-informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data. Pharmacoepidemiol Drug Saf. 2022; 32(3):352-365. PMC: 10947320. DOI: 10.1002/pds.5567. View

4.
Blanch B, Daniels B, Litchfield M, Pearson S . Looking forward and looking back: the balancing act in new drug user designs for pharmacoepidemiological research. Pharmacoepidemiol Drug Saf. 2015; 24(10):1117-9. DOI: 10.1002/pds.3848. View

5.
Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir A, Sorensen H . The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2009; 106(2):86-94. DOI: 10.1111/j.1742-7843.2009.00494.x. View